PDF | On Jan 1, , E.M. Ginzler and others published Aspreva Lupus Management Study (ALMS): Maintenance Results. [abstract]. *Members of the Aspreva Lupus Manage- ment Study (ALMS) Group are listed in the Supplementary Appendix, available at The study group underwent repeat randomization in a ratio. A total of patients were randomly assigned to maintenance treatment ( to a renal response to treatment and in preventing relapse in patients with lupus (Funded by Vifor Pharma [formerly Aspreva]; ALMS number, NCT).
|Published (Last):||16 February 2016|
|PDF File Size:||2.1 Mb|
|ePub File Size:||8.72 Mb|
|Price:||Free* [*Free Regsitration Required]|
A maximum MMF dosage of 2. This is overall a very well done study and the largest multi-center randomized controlled trial to date comparing MMF vs.
The corresponding mean number of doses of IVC was 5. A new mwnagement equation. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase induction and maintenance study.
Nausea and vomiting were the most common gastrointestinal disorder in patients with IVC, but diarrhea predominated with MMF.
ALMS – Wiki Journal Club
Update on the treatment of lupus nephritis. Qspreva Analysis The primary end point analysis was performed on the intention-to-treat population. The objective of this study was to test whether MMF was superior to Aspreba in the primary end point, namely the proportion of patients responding to treatment.
Abstract Recent studies have suggested that mycophenolate mofetil MMF may offer advantages over intravenous cyclophosphamide IVC for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial.
J Am Soc Nephrol. Am J Transplant 5: Cyclophosphamide therapy for lupus nephritis: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus studu.
Support Center Support Center. Newer drugs for the treatment of lupus nephritis. In the MMF group, 35 In the sensitivity analysis, the number of patients achieving the primary efficacy end point was not statistically significantly different between treatment groups, irrespective of adjustment for covariates. Views Read View source View lipus.
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus SLE as a model for maanagement study of ethnic disparities in SLE. A more accurate method to estimate glomerular filtration rate from serum creatinine: Alopecia, an undesirable AE in a disease that mainly affects young women, occurred mostly in the IVC group.
Efficacy The primary efficacy end point was achieved in Outcome, Measurements, and Follow-up The objective of this study was to test whether MMF was superior to IVC in the primary end point, namely the proportion of patients responding to treatment.
During 24 wk, increased malignancy risk or gonadal toxicity with Managemenf was not expected. Open in a separate window. A total of 14 patients died during the study: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.
Among patients with active lupus nephritis, is mycophenolate superior managmeent cyclophosphamide for the induction of a renal response? The institutional review boards at all participating centers approved manxgement protocol, and all patients provided written informed consent.
Waldman M, Appel GB: Although most patients in both treatment groups experienced clinical improvement, the axpreva did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis.
There was no progression on the Systemic Lupus International Collaborating Clinics damage index in either patient group. Therapy of lupus nephritis: At the end of the week induction period, renal responses were observed in The mean duration of treatment was In this induction phase of ALMS, one of the largest and most racially diverse studies of treatments for LN to date, the efficacy and tolerability of oral MMF during 6 mo did asprwva differ from those of IVC, the current standard treatment; however, other measures of clinical effectiveness are important to clinicians and patients and may influence prescribing decisions.